Low expression of SHP-2 is associated with less favorable prostate cancer outcomes

DSpace Repository

Low expression of SHP-2 is associated with less favorable prostate cancer outcomes

Overview

Detailed record

dc.contributor.author Tassidis, Helena
dc.contributor.author Brokken, Leon JS
dc.contributor.author Jirström, Karin
dc.contributor.author Bjartell, Anders
dc.contributor.author Ulmert, David
dc.contributor.author Härkönen, Pirkko
dc.contributor.author Gjörloff Wingren, Anette
dc.date.accessioned 2013-05-06T08:23:40Z
dc.date.available 2013-05-06T08:23:40Z
dc.date.issued 2013 en_US
dc.identifier.issn 1010-4283 en_US
dc.identifier.uri http://hdl.handle.net/2043/15377
dc.description.abstract Src homology 2 domain-containing tyrosine phosphatase-2 (SHP-2) is an important regulator of cell signaling because of its ability to dephosphorylate receptors of growth factors as well as the cytokines and tyrosine-phosphorylated proteins associated with these receptors. In the current study, we used four different prostate cancer cell lines: PC3, DU145, LNCaP and LNCaP-IL6+. Tumor specimens from 122 patients with prostate cancer were analyzed using a tissue microarray. Our data demonstrate that all four prostate cancer cell lines express the SHP-2 protein. Additionally, low staining intensity and SHP-2 expression in the cytoplasm of cancer cells in prostate tumor specimens was inversely correlated with prostate volume (p = 0.041 and p = 0.042, respectively) whereas nuclear staining was positively correlated with extracapsular extension (p = 0.039). In our post-prostatectomy specimens, we found that patients with low SHP-2 expression had less favorable outcomes with respect to biochemical recurrence and clinical progression (p = 0.005 and p = 0.018, respectively). The loss of cytoplasmic SHP-2 expression is associated with increased growth and prostatic cancer progression. en_US
dc.format.extent 6
dc.language.iso eng en_US
dc.publisher Springer en_US
dc.subject Src homology 2 domain-containing tyrosine phosphatase-2 (SHP-2) en_US
dc.subject Prostate cancer en_US
dc.subject Tissue microarray (TMA) en_US
dc.subject.classification Medicine en_US
dc.title Low expression of SHP-2 is associated with less favorable prostate cancer outcomes en_US
dc.type Article, peer reviewed scientific en_US
dc.contributor.department Malmö University. Faculty of Health and Society en_US
dc.contributor.department Malmö University. Biomedical Sciences (BMV) en_US
dc.identifier.doi 10.1007/s13277-012-0590-1 en_US
dc.subject.srsc Research Subject Categories::MEDICINE en_US
dc.relation.ispartofpublication Tumor Biology;2
dc.relation.ispartofpublicationvolume 34 en_US
dc.format.ePage 642
dc.format.sPage 637
mahlocal.rights.oaType green
 Find Full text Files for download
Icon
Författarversion, ...

This item appears in the following Collection(s)

Overview

Search


Browse

My Account

Statistics